| PET/CT using 18F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. | |
| | |
MedLine Citation:
|
PMID: 22183015 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
AIM: In Canada, staging of carcinoid tumors is largely based on computed tomography (CT) imaging sometimes complemented with somatostatin receptor scintigraphy (SRS). This study assessed the diagnostic accuracy of 6-[F]fluoro-3,4-dihydroxyphenylalanine (F-FDOPA) PET/CT in neuroendocrine tumors. METHODS: We prospectively included 27 patients with either suspected carcinoid (n=6, with all prior tests negative) or with an established diagnosis of intestinal carcinoid tumor (n=21) from two Canadian treatment centers. Findings of F-FDOPA PET/CT were compared with SRS, CT, and combined SRS/CT using a composite reference standard comprising all available imaging, biochemistry, surgery, and follow-up data. Sensitivity was calculated per patient, per body region, and per lesion. The contribution to patient management was estimated from the feedback of attending physicians. RESULTS: In documented carcinoid patients, F-FDOPA PET/CT identified disease in 20 of 21 patients (patient-based sensitivity 95%). In 56 positive regions, F-FDOPA PET/CT detected 53, CT detected 34, SRS detected 34, and CT+SRS detected 39 regions, leading to region-based sensitivities of 95, 61, 62, and 71%, respectively. Lesion-based sensitivities were 96, 69, 50, and 72%, respectively. In the six patients with suspected disease only, one CT scan was positive, but F-FDOPA PET/CT was negative for all. F-FDOPA PET contributed to patient management in 12/21 patients (57%). CONCLUSION: F-FDOPA PET/CT proved to be an excellent modality for staging of carcinoid tumor patients, with superior performance compared with currently applied methods in Canada. In patients with suspected disease with negative prior imaging investigations, F-FDOPA was not helpful. |
| | |
Authors:
|
Valerie N Yakemchuk; Pieter L Jager; Raman Chirakal; Robert Reid; Pierre Major; Karen Y Gulenchyn |
Related Documents
:
|
21786435 - Application of magnetic resonance imaging and magnetic resonance angiography as diagnos... 18225855 - Accuracy of ultrasound to mr registration of the knee. 22112805 - Evaluation of the sensitivity and specificity of 11c-metomidate positron emission tomog... 8204405 - Head surface digitization and registration: a method for mapping positions on the head ... 12271395 - Mri and color-coded duplex sonography: diagnosis of partial priapism. 20379545 - Towards mri microarrays. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-16 |
Journal Detail:
|
Title: Nuclear medicine communications Volume: - ISSN: 1473-5628 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-20 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8201017 Medline TA: Nucl Med Commun Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
aDepartment of Nuclear Medicine, Hamilton Health Sciences bMcMaster University cJuravinski Cancer Center, Hamilton dLondon Health Sciences Center, London, Ontario, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bimetallic nanowires as electrocatalysts for nonenzymatic real-time impedancimetric detection of glu...
Next Document: Specific and reversible photochemical labeling of plasmid DNA using photoresponsive oligonucleotides...